References
- Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230–6.
- The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke J Am Med Assoc 2002;288:2015–22.
- Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31–62.
- Nygárd O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. J Am Med Assoc 1995;274:1526–33.
- Myllykangas-Luosujärvi RA, Aho K, Isomäki HA. Morta-lity in rheumatoid arthritis. Semin Arthritis Rheum 1995; 25:193–202.
- Wällberg Jonsson S, Qhman ML, Rantapää Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 1997;24:445–51.
- Milberg Jonsson S, Backman C, Johnson O, Karp K, Lundstrom E, Sundqvist KG, et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001;28:2597–602.
- del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
- Wallberg Jonsson S, Johansson H, Qhman M-L, Rantapää Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562–71.
- Pettersson T, Friman C, Abrahamsson L, Nilsson B, Norberg B. Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia. J Rheumatol 1998;25:859–63.
- Hernanz A, Plaza A, Martin-Mola E, de Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999;32:65–70.
- Roubenoff R, Dellaripa P, Nadeau MR, Abad LW, Muldoon BA, Selhub J, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997; 40:718–22.
- Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of athero-thrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002;29:875–82.
- Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long term, low dose Metho-trexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25:441–6.
- Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol 2001; 30:305–7.
- Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJG. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoetin responsive-ness. Ann Rheum Dis 1990;49:93–8.
- Roubenhoff R, Roubenhoff RA, Selhub J, Nadeau MR, Cannon JG, Freeman LM, et al. Abnormal vitamin B6 status in rheumatoid cachexia: Association with spontaneous tumour necrosis factor a production and markers of inflammation. Arthritis Rheum 1995;38:105–9.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
- Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
- Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanism of action of methotrexate. Immunopharma-cology 2000;47:247–57.